Inte:Ligand assists scientists and management in the pharmaceutical, life science and cosmetic industries to improve their efficiency in identifying new bio-active molecules. We develop and deliver innovative scientific software solutions as well as expert consulting that facilitate the decision making process for prioritizing compounds for further experimental assessment.
Inte:Ligand is a software company headquartered in Vienna, Austria. It provides software and services for chemical research, especially in the areas of drug discovery. Started in 2003 as a spin-off of the University of Innsbruck and was founded by Prof. Thierry Langer, Dr. Gerhard Wolber and Prof. Hermann Stuppner.
Researchers and scientists at Inte:Ligand have developed technologyfor 3D pharmacophore development and virtual screening used in early drug development stages to make drug discovery more efficient to prevent failures in clinical trials. Applications include the discovery of new Myeloperoxidase ligands, HIV reverse transcriptase inhibitors, applications in anti-viral bio-activity profiling, the development of models to predict HIV Protease activity, Cytochrome P450 activity prediction, and simulation models for the activity on Factor Xa.
The business concept of Inte:Ligand is targeted on offering new technologies to the pharmaceutical industry in order to make drug development faster, more efficient and more economical. Inte:Ligand is developing novel integrated software solutions, which will revolutionize lead structure discovery and optimization and, in addition, will permit the analysis of potential side effect and risks.
Thus the R&D processes at the beginning of drug development (early discovery phase) are substantially optimized and accelerated, as well as the dropout rate and thus the risk reduced. Therefore through the know-how and the tools of Inte:Ligand, we enable our customers to substantially reduce their drug development costs.
More information on Inte:Ligrad